Hetero has partnered with Gilead Sciences to manufacture and distribute the HIV drug lenacapavir in 120 low- and ...
Lenacapavir was approved for use in HIV-positive adults with multi-drug resistance by the European Union in August 2022 and ...
Hetero and Gilead have partnered to expand access to lenacapavir, a groundbreaking HIV treatment, in 120 low- and ...
Dr Reddy's Laboratories and Hetero sign non-exclusive, royalty-free agreements with Gilead Sciences to manufacture ...
Dr. Reddy’s and Hetero partner with Gilead Sciences to manufacture and distribute Lenacapavir for HIV treatment in LMICs.
Dr Reddy's Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with ...
With women, as Étienne had somehow sensed, I’m a very attentive, confident, and giving top. My pleasure comes mostly from ...
Gilead Sciences first launched lenacapavir under the brand name Sunlenca in the United States and European markets in 2022. It is a first-in-class HIV-1 capsid inhibitor ...
Gilead Sciences, Inc. has announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six ...
Researchers have developed a novel passivation process for formamidinium lead iodide perovskite films, which reportedly ...
A study led by the Gwangju Institute of Science and Technology (GIST) developed the new defect passivation strategy. The ...